
{"publication_number": "US-2017095479-A1", "abstract": "the present invention relates generally to the use of gene mutations , whose presence or absence are useful for predicting a patient &# 39 ; s response to treatment with an anti - proliferative agent , in particular a wee1 inhibitor . the presence or absence of a mutation to the tp53 gene , can be used to predict response to treatment with a wee1 inhibitor in a patient presenting with a cancerous condition .", "application_number": "US-201515314650-A", "description": "many anti - cancer treatments act by damaging dna , which subsequently initiates the dna damage response ( ddr ) and activates checkpoint kinases to arrest division while the dna is repaired . wee1 , a tyrosine kinase , is activated by the ddr to phosphorylate and inhibit cyclin dependent kinases ( cdks ) 1 and 2 and , as such , arrest cell division . inhibiting wee1 potentiates dna damaging treatments by abrogating cell cycle arrest and proper dna repair . wee1 - 1 , also known as 2 - allyl - 1 -[ 6 -( 1 - hydroxy - 1 - methylethyl ) pyridin - 2 - yl ]- 6 -{[ 4 -( 4 - methylpiperazin - 1 - yl ) phenyl ] amino 